Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy and Asthma Specialists, PSC

Neither a doctor nor a teaching hospital

Research payments

$673,086

183 payments

Through program year 2025, Allergy and Asthma Specialists, PSC is reported as receiving $673,086 in research payments, across 183 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $201,800 35
2024 Research $108,345 29
2023 Research $86,244 26
2022 Research $110,898 40
2021 Research $117,710 40
2020 Research $33,873 6
2019 Research $14,216 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $273,493 96 payments
  2. Genzyme Corporation $271,428 74 payments
  3. Novartis Pharmaceuticals Corporation $123,166 12 payments
  4. AstraZeneca UK Limited $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $200,628 60 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze $84,826 20 payments
  3. A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment $77,940 36 payments
  4. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab $67,738 27 payments
  5. A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $66,084 1 payment
  6. A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma $62,700 13 payments
  7. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Open-Label Extension Study Followed By Long-Term Open-Label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (Lou064) in Adult Chronic Spontaneous U $35,983 1 payment
  8. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma $17,000 6 payments
  9. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients na $11,836 2 payments
  10. A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment $10,100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record